C
C. Dean Buckner
Researcher at University of Washington
Publications - 62
Citations - 5700
C. Dean Buckner is an academic researcher from University of Washington. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 34, co-authored 62 publications receiving 5602 citations. Previous affiliations of C. Dean Buckner include Fred Hutchinson Cancer Research Center & University of Iowa.
Papers
More filters
Journal ArticleDOI
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb,H. Joachim Deeg,John Whitehead,Frederick R. Appelbaum,Patrick G. Beatty,William I. Bensinger,C. Dean Buckner,Reginald A. Clift,Kristine Doney,Vernon T. Farewell,J. D. Hansen,Roger Hill,Lawrence G. Lum,Paul J. Martin,Robert W. McGuffin,Jean E. Sanders,Patricia S. Stewart,Keith M. Sullivan,Robert P. Witherspoon,Gary Yee,E. Donnall Thomas +20 more
TL;DR: It is concluded that the combination of methotrexate and cyclosporine is superior to cyclOSporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.
Journal ArticleDOI
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer
John Nemunaitis,John Nemunaitis,John Nemunaitis,SN Rabinowe,Jack W. Singer,Jack W. Singer,Jack W. Singer,Philip J. Bierman,Julie M. Vose,Arnold S. Freedman,Nicole Onetto,S Gillis,Dagmar Oette,Morris S. Gold,C. Dean Buckner,C. Dean Buckner,John A. Hansen,John A. Hansen,Jerome Ritz,Frederick R. Appelbaum,Frederick R. Appelbaum,James O. Armitage,Lee M. Nadler +22 more
TL;DR: The patients given rhGM-CSF had a recovery of the neutrophil count to 500×106 per liter 7 days earlier than the patients who received placebo, suggesting that recombinant human granulocytemacrophage colony-stimulating factor may accelerate neutrophIL recovery and thereby reduce complications in patients after autologous bone marrow transplantation.
Journal ArticleDOI
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation
William I. Bensinger,Reginald A. Clift,Paul J. Martin,Frederick R. Appelbaum,Taner Demirer,Ted Gooley,K Lilleby,Scott D. Rowley,Jean E. Sanders,Rainer Storb,C. Dean Buckner +10 more
TL;DR: This retrospective comparison suggests that compared to marrow transplantation from HLA-identical donors, allogeneic PBSC transplants from Hla-Identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of acute or chronic GVHD.
Journal ArticleDOI
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
Keith M. Sullivan,Kenneth J. Kopecky,Jane Jocom,L D Fisher,C. Dean Buckner,Joel D. Meyers,George W. Counts,Raleigh A. Bowden,Finn Bo Petersen,Robert P. Witherspoon,Miriam D. Budinger,Richard S. Schwartz,Frederick R. Appelbaum,Reginald A. Clift,John A. Hansen,Jean E. Sanders,E. Donnall Thomas,Rainer Storb +17 more
TL;DR: Passive immunotherapy with intravenous immunoglobulin decreases the risk of acute GVHD, associated interstitial pneumonia, and infections after bone marrow transplantation.
Journal ArticleDOI
Predictive Factors in Chronic Graft-Versus-Host Disease in Patients with Aplastic Anemia Treated by Marrow Transplantation from HLA-Identical Siblings
Rainer Storb,Ross L. Prentice,Keith M. Sullivan,Howard M. Shulman,H. Joachim Deeg,Kristine Doney,C. Dean Buckner,Reginald A. Clift,Robert P. Witherspoon,Appelbaum Fa,Jean E. Sanders,Patricia S. Stewart,E. Donnall Thomas +12 more
TL;DR: The authors' analysis, using a binary logistic regression model, identified three factors predicting chronic graft-versus-host disease: moderate to severe acute graft-Versus- host disease with an estimated relative risk of 11.65; increasing patient age; and the use of viable donor buffy coat cells in addition to the marrow to prevent graft rejection.